What is the success rate of Rituxan (rituximab) in patients with blood cancers?

Q: What is the success rate of Rituxan (rituximab) in patients with blood cancers?

In patients with hematological or blood cancers, including non-Hodgkin's lymphoma (NHL) and chronic lymphocytic leukemia (CLL), Rituxan’s success is measured in a number of ways. It is measured by looking at how long patients responded to treatment (median duration of response), how long they live without their disease progressing (progression-free survival) and how many patients respond to treatment (response rate). Rituxan treatment improves outcomes in certain patients with NHL. Adding Rituxan alongside standard therapies enhances the response patients have to treatment and improves overall outcomes, including increasing the time patients live for without experiencing a progression of their disease. Rituxan helps to improve overall survival in certain patients with CLL and also helps to increase the time patients live for without experiencing disease progression. Adding Rituxan alongside standard therapy enhances the response patients have to therapy.

Medically reviewed by Philip Thornton, DipPharm. Last updated on March 26, 2025.

Official Answer by Drugs.com

Rituxan (rituximab) is a monoclonal antibody that works by targeting the CD20 protein antigen displayed on the surface of B-cells. It is used in the treatment of a variety of conditions including non-Hodgkin's lymphoma (NHL), chronic lymphocytic leukemia (CLL), rheumatoid arthritis, granulomatosis with polyangiitis (GAP) and moderate to severe pemphigus.

In patients with hematological or blood cancers, including NHL and CLL, Rituxan’s success is measured in a number of ways:

How long patients responded to treatment (median duration of response)
How long patients live without their disease progressing (progression-free survival)
How many patients respond to treatment (response rate)

How effective is Rituxan in people with non-Hodgkin’s lymphoma?

Rituxan improves response rates and survival outcomes in NHL patients, particularly when combined with chemotherapy.

NHL patient group	Measure of success
Relapsed or refractory, low grade or follicular, CD20-positive B-cell NHL as a single agent (Results from three single-arm studies in 296 patients)	Median duration of response Rituxan weekly for 4 weeks. 11.2 months (1.9 to 42.1+) Rituxan weekly for 8 weeks. 13.4 months (2.5 to 36.5+) Rituxan weekly for 4 weeks in patients with bulky disease. 6.9 months (2.8 to 25.0+) Rituxan retreatment weekly for 4 weeks. 15.0 months (3.0 to 25.1+) Overall response rate (including complete and partial responses) Rituxan weekly for 4 weeks. 48% Rituxan weekly for 8 weeks. 57% Rituxan weekly for 4 weeks in patients with bulky disease. 36% Rituxan retreatment weekly for 4 weeks. 38% Complete response rate Rituxan weekly for 4 weeks. 6% Rituxan weekly for 8 weeks. 14% Rituxan weekly for 4 weeks in patients with bulky disease. 3% Rituxan retreatment weekly for 4 weeks. 10%
Previously untreated follicular, CD20-positive, B-cell NHL in combination with first line chemotherapy and, in patients achieving a complete or partial response to a rituximab product in combination with chemotherapy, as single-agent maintenance therapy + Non-progressing (including stable disease), low-grade, CD20 positive, B-cell NHL as a single agent after first-line cyclophosphamide, vincristine, and prednisone (CVP) chemotherapy (Results from three randomized controlled trials in 1662 patients)	Median progression-free survival Rituxan + CVP chemotherapy. 2.4 years vs CVP chemotherapy alone. 1.4 years (P<0.0001) Rituxan maintenance therapy following treatment with Rituxan + chemotherapy increased progression-free survival compared with patients who did not receive maintenance therapy - hazard ratio 0.54 (95% CI 0.42, 0.70) In patients previously treated with CVP chemotherapy, maintenance treatment with Rituxan reduced the risk of progression, relapse or death compared with patients who did not receive maintenance therapy - hazard ratio range 0.36 to 0.49
Previously untreated diffuse large B-cell, CD20-positive NHL in combination with (cyclophosphamide, doxorubicin, vincristine, and prednisone) (CHOP) or other anthracycline-based chemotherapy regimens (Results from three randomized, active-controlled, open-label, multicenter trials in 1854 patients)	Progression-free survival Rituxan + CHOP. 3.1 years vs CHOP. 1.6 years Event-free survival Rituxan + CHOP. 2.9 years vs CHOP. 1.1 years Time to treatment failure Rituxan + chemo - not able to be estimated vs Chemo - not able to be estimated

How effective is Rituxan in people with chronic lymphocytic leukemia?

Rituxan helps to improve overall survival in certain patients with CLL and also helps to increase the time patients live for without experiencing disease progression. Adding Rituxan alongside standard therapy enhances the response patients have to therapy.

Chronic lymphocytic leukemia patient group

Measure of success

Previously untreated CD20-positive CLL in combination with fludarabine and cyclophosphamide (FC)

(Results from one randomized multicenter open-label study in 817 patients)

Median progression-free survival

Rituxan + FC. 39.8 months
vs
FC. 31.5 months (p<0.01)

Overall response rate

Rituxan + FC. 86% (95% CI, 82, 89)
vs
FC. 73% (95% CI, 68, 77)

Previously treated CD20-positive CLL in combination FC

(Results from one randomized multicenter open-label study in 552 patients)

Median progression-free survival

Rituxan + FC. 26.7 months
vs
FC. 21.7 months (p=0.02)

Overall response rate

Rituxan + FC. 54% (95% CI, 48, 60)
vs
FC. 45% (95% CI, 37, 51)

Conclusion

Rituxan significantly improves response rates and survival outcomes in NHL and CLL, particularly when combined with chemotherapy. Patients should discuss treatment options with their healthcare provider to determine the best approach based on their specific condition.

References

Food and Drug Administration (FDA). Rituxan. [Accessed October 6, 2021]. Available from: https://www.accessdata.fda.gov/drugsatfda_docs/label/2021/103705s5464lbl.pdf.

What is the success rate of Rituxan (rituximab) in rheumatoid arthritis?

Treatment with Rituxan (rituximab) successfully improves patient outcomes in patients with rheumatoid arthritis including reducing symptoms, reducing levels of fatigue and disability, and increasing health-related quality of life. It also slows the progression of structural damage in joints. Continue reading

What causes infusion reactions to rituximab?

Rituximab infusion reactions are caused primarily by cytokine release in the body. Cytokines are immune system proteins in the body that help to fight infections but can cause an inflammatory response. Infusion reactions may cause hives, itching, shortness of breath, chest pain or dizziness and are a very common side effect of treatment with rituximab (Rituxan). Continue reading

What is the difference between Rituxan and Rituxan Hycela?

Rituxan (rituximab) is administered intravenously (IV), while Rituxan Hycela is given subcutaneously (SC). Continue reading

What is the success rate of Rituxan (rituximab) in patients with blood cancers?

How effective is Rituxan in people with non-Hodgkin’s lymphoma?

Related questions

How effective is Rituxan in people with chronic lymphocytic leukemia?

Conclusion

Read next

What is the success rate of Rituxan (rituximab) in rheumatoid arthritis?

What causes infusion reactions to rituximab?

What is the difference between Rituxan and Rituxan Hycela?

See also:

Aimovig

Botox

Imbruvica

Nurtec ODT

Vyepti

Depakote

Topamax

Emgality

Inderal

Ajovy

Related medical questions

Drug information

Related support groups